Home > PORTAL > about Us > Presentation >
Learn how SPIN got started
SPIN – Skin Inflammation & Psoriasis International Network was initiated in 2004 as PIN – Psoriasis International Network by the FRT - Fondation René Touraine, a non-profit and a non-governmental organisation dedicated to support therapeutic progress in dermatology by fostering international collaborations.
After several European meetings on psoriasis held in Italy every 2 or 3 years, the FRT and Prof. Louis Dubertret organised the European Congress on Psoriasis - PSO 2004 in Paris, which acquired a great international dimension, with over 600 participants from 40 different countries. Following the PSO 2004 Congress, many participants showed great interest in developing networking activities in the field of psoriasis.
The founding meeting of the former PIN was held in Paris (Nov 18, 2005) between 20 countries willing to develop national psoriasis groups and willing to connect these groups into an international network. 11 countries were able to send a representative and 9 additional countries expressed a strong interest but were unable to come. The President of EUROPSO, the European federation of psoriasis associations, participated as well in the founding meeting.
This founding meeting formalised the international collaborations in the field of psoriasis started with the PSO 2004 Congress, creating thus the Psoriasis International Network. To develop this international network, it was proposed to:
• set up a website: www.psoriasis-international.org (now www.spindermatology.org!)
• organise every 3 years an International Congress on Psoriasis in Paris
• publish regular newsletters and "Focus On”
In 2011, a Scientific Committee was created to steer the scientific development of the network by proposing international collaborative projects, contributing to continuing medical training in psoriasis and supporting the development of national and regional psoriasis networks.
The network has grown ever since, gathering around 4700 healthcare professionals involved in the management of psoriasis from some 100 countries, 330 dermatology centres as well as 43 patient organisations. Since 2004, PIN has successfully:
• organised 5 international congresses on psoriasis and educational symposia during other dermatology meetings
• built a worldwide directory listing psoriasis medical resources for patients
• provided organisational support to the development of dedicated outpatient consultations at the local level
• fostered the development of national and regional networks on psoriasis
• carried out international studies on the current practice of the use of methotrexate and phototherapy in the treatment of psoriasis
• initiated a worldwide survey on the use of therapeutic patient education in psoriasis with the aim of developing a toolbox
• collaborated with the EADV Psoriasis Task Force since 2005.
In 2016, it was decided by the FRT Board of Directors to broaden the scope of the PIN to include other major chronic inflammatory skin diseases. This would allow to benefit from the benchmark of PIN’s actions and achievements in psoriasis and put it to the service of other diseases. With this change, we hope to transfer the know-how acquired on psoriasis (highest standard in issues such as quality of life, high burden and co-morbidities) and build on the collaborations made possible via the PIN network and expand them to other major chronic skin inflammatory diseases.
Following this decision, the former PIN Scientific Committee has decided to change the name of the network to SPIN – Skin Inflammation & Psoriasis International Network. On an operational level, the Committee decided to broaden the network’s scope progressively, one chronic inflammatory skin disease at a time. Starting in 2017, the new SPIN will cover psoriasis and expand its activities to atopic dermatitis.
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
Bioorg. Med. Chem. Lett..
2020 Aug 15, 30, (16):127298.
We report on the discovery of the new clinical candidate BAY 1003803 as glucocorticoid receptor agonist for the topical treatment of psoriasis or severe atopic dermatitis. In the course of optimizing the amino alcohol series as a highly potent new non-steroidal lead structure, considerations were made as to how physicochemical properties and safety concerns relate to structural motifs. BAY 1003803 demonstrates strong anti-inflammatory activity in vitro paired with a pharmacokinetic profile (...)
see on pubmed
Immobilization of papain enzyme on a hybrid support containing zinc oxide nanoparticles and chitosan for clinical applications.
Carbohydr Polym.
2020 Sep 01, 243:116498.
A new hybrid bionanomaterial composed of zinc oxide nanoparticles (ZnO NPs) and chitosan was constructed after enzymatic immobilization of papain for biomedical applications. In this work, we report the preparation and characterization steps of this bionanomaterial and its biocompatibility in vitro. The properties of the immobilized papain system were investigated by transmission electron microscopy, zeta potential, DLS, UV-vis absorption spectroscopy, FTIR spectroscopy, and X-ray (...)
see on pubmed
Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.
Drug Deliv.
2020 Dec , 27, (1):662-680.
Psoriasis is a dermatological chronic skin condition with underlying autoimmune etiology. It deeply affects patients' quality of life. Therefore, it was an interesting target for researchers throughout the past years. Conventionally, the treatment options include anti-inflammatory agents, immune suppressants, biologic treatment, and phototherapy. Nanotechnology offers promising characteristics that allow for tailoring a drug carrier to achieve dermal targeting, improved efficacy and (...)
see on pubmed
on Atopic Dermatitis
Diagnostic Models for Atopic Dermatitis Based on Serum Microbial Extracellular Vesicle Metagenomic Analysis: A Pilot Study.
Allergy Asthma Immunol Res.
2020 Sep , 12, (5):792-805.
Associations between a wide variety of diseases and the microbiome have been extensively verified. Recently, there has been a rising interest in the role the microbiome plays in atopic dermatitis (AD). Furthermore, metagenomic analysis of microbe-derived extracellular vesicles (EVs) has revealed the importance and relevance of microbial EVs in human health.
see on pubmed
Mitochondrial and Nuclear Mitochondrial Variants in Allergic Diseases.
Jang H et al.
Mitochondrial and Nuclear Mitochondrial Variants in Allergic Diseases.
Allergy Asthma Immunol Res.
2020 Sep , 12, (5):877-884.
The mitochondrial genome encodes core catalytic peptides that affect major metabolic processes within a cell. Here, we investigated the association between mitochondrial DNA (mtDNA) variants and allergic diseases, including atopic dermatitis (AD) and asthma, alongside heteroplasmy within the mtDNA in subjects with allergic sensitization. We collected genotype data from 973 subjects with allergic sensitization, consisting of 632 children with AD, 498 children with asthma, and 481 healthy (...)
see on pubmed
Update on canine filaggrin: a review.
Combarros D et al.
Update on canine filaggrin: a review.
Vet Q.
2020 Dec , 40, (1):162-168.
Human filaggrin (FLG) plays a key role in epidermal barrier function, and loss-of-function mutations of its gene are primarily responsible for the development of human atopic dermatitis (AD). FLG expression is also reduced in the epidermis of atopic patients, due to the transcriptional effect of Th2 type cytokines. Canine atopic dermatitis (CAD) is a prevalent skin disease that shares many clinical and pathogenic features with its human homologue. The aim of this review is discuss current (...)
see on pubmed
